Articles
Currently, cholinesterase inhibitors are the mainstay in clinical practice of symptomatic treatment for Alzheimer’s disease (AD). They are believed...
This delay in recognition of AD as a major neurological disease of aging does not reflect its impact.There are the personal tragedies that accompany...
Furthermore, in most studies, the role of tau has been understated for a long time. To apprehend this role, the Inserm team has developed a...
Another common form of dementia is Lewy body dementia (LBD). As its name suggests, LBD is characterized by the presence of Lewy bodies—...
Natural History of Alzheimer’s Disease The natural history of AD can be broadly considered as comprising a pre-symptomatic stage during which...
In this article, we will consider the clinical, neurochemical, and pathological features of the various types of DLB, review therapeutic strategies...
The following interventions need to be considered in a patient with neurodegenerative dementia of the ‘Alzheimer type’. Symptomatic...
A number of genetic and non-genetic factors may influence the development of AD. Mutations in genes on chromosomes 14, 1, and 21, which increase...
Acetylcholine is a major neurotransmitter in the hippocampus,13 and memory failure in ageing and AD is hypothesised to result from impairment of the...
Treatment Response in Alzheimer's Disease Ever since the licensing of cholinesterase inhibitors (ChEIs) and memantine for the treatment of AD, there...
Treatment Response in Alzheimer’s DiseaseEver since the licensing of cholinesterase inhibitors (ChEIs) and memantine for the treatment of AD,...
Current pharmacotherapy is focused on delaying the symptomatic progression of AD. Although the cause of the disease remains unknown, acetylcholine...
Although there have been tremendous developments in the understanding of the molecular biology of Alzheimer’s disease (AD), this has not yet been...
Each of these stages can be targeted for specific drug treatments, requiring different trial designs and outcomes: • a healthy elderly...
The cholinesterase inhibitors are clearly palliative therapies. Since the late 1970s it has been known that there is a cholinergic deficit in the...
The AD Neuroimaging Initiative Last fall, the NIA, a component of the National Institutes of Health (NIH), and its partners began funding the AD...
Acetylcholinesterase Inhibitors Research has shown that the amount of a chemical called acetylcholine diminishes in the brains of people with...
